Renaissance Capital logo

Bright Green Priced, Nasdaq: BGXX

Federally-authorized US provider of cannabis products for medicinal research.

Industry: Health Care

Latest Trade: $0.12 -0.01 (-4.0%)

First Day Return: +215.6%

Return from IPO: -98.4%

Industry: Health Care

Bright Green’s mission is to be the premier federally-authorized provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured in exact formulations for research and pharmaceutical applications, as well as being an active ingredient to consumer-based solutions. The Company, through legal partnerships with state and federal agencies, can operate at scale in a manner unprecedented in this emerging market, addressing compliance, security and integrity. Our vision is to improve the quality of life across a broad spectrum of demographics through the opportunities presented by medicinal applications of plant-based therapies, particularly cannabis and cannabis-derived products. We are a first-mover in the U.S. federally-licensed cannabis space. We are one of a few companies who have received conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration (the “DEA”) to produce federally legal cannabis, and have entered into a Memorandum of Agreement (“MOA”) with the DEA which permits us to proceed towards a Federal Registration for the Bulk Manufacturing of cannabis under DEA Document Control Number W20078135E.
more less
IPO Data
IPO File Date 03/29/2022
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 158.2
Deal Size ($mm) $0
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/17/2022
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 158.2
Deal Size ($mm) $0
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
EF Hutton
Company Data
Headquarters Fort Lauderdale, FL, United States
Founded 2019
Employees at IPO 2
Website www.brightgreen.us

Bright Green (BGXX) Performance